Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models
- PMID: 19252273
- DOI: 10.1248/bpb.32.332
Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models
Abstract
Multiple lines of evidence, from molecular and cellular to epidemiological, have implicated nicotinic transmission in the pathology of Alzheimer's disease (AD) and Parkinson's disease (PD). This review article presents evidence for nicotinic acetylcholine receptor (nAChR)-mediated protection and the signal transduction involved in this mechanism. The data is based mainly on our studies using rat-cultured primary neurons. Nicotine-induced protection was blocked by an alpha7 nAChR antagonist, a phosphatidylinositol 3-kinase (PI3K) inhibitor, and an Src inhibitor. Levels of phosphorylated Akt, an effector of PI3K, Bcl-2 and Bcl-x were increased by nicotine administration. From these experimental data, our hypothesis for the mechanism of nAChR-mediated survival signal transduction is that the alpha7 nAChR stimulates the Src family, which activates PI3K to phosphorylate Akt, which subsequently transmits the signal to up-regulate Bcl-2 and Bcl-x. Up-regulation of Bcl-2 and Bcl-x could prevent cells from neuronal death induced by beta-amyloid (Abeta), glutamate and rotenone. These findings suggest that protective therapy with nAChR stimulation could delay the progress of neurodegenerative diseases such as AD and PD.
Similar articles
-
Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity.Biol Psychiatry. 2001 Feb 1;49(3):233-9. doi: 10.1016/s0006-3223(00)01100-8. Biol Psychiatry. 2001. PMID: 11230874 Review.
-
Astrocytic α7 Nicotinic Receptor Activation Inhibits Amyloid-β Aggregation by Upregulating Endogenous αB-crystallin through the PI3K/Akt Signaling Pathway.Curr Alzheimer Res. 2019;16(1):39-48. doi: 10.2174/1567205015666181022093359. Curr Alzheimer Res. 2019. PMID: 30345917
-
Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity.Biochem Biophys Res Commun. 2004 Dec 17;325(3):976-82. doi: 10.1016/j.bbrc.2004.10.132. Biochem Biophys Res Commun. 2004. PMID: 15541385
-
α7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson's disease.Curr Drug Targets. 2012 May;13(5):623-30. doi: 10.2174/138945012800399026. Curr Drug Targets. 2012. PMID: 22300030 Review.
-
Enhancement of nicotinic receptors alleviates cytotoxicity in neurological disease models.Ther Adv Chronic Dis. 2011 May;2(3):197-208. doi: 10.1177/2040622310397691. Ther Adv Chronic Dis. 2011. PMID: 23251750 Free PMC article.
Cited by
-
Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Drugs. 2011 Oct 22;71(15):2031-65. doi: 10.2165/11595870-000000000-00000. Drugs. 2011. PMID: 21985169 Review.
-
Critical Roles of Glutaredoxin in Brain Cells-Implications for Parkinson's Disease.Antioxid Redox Signal. 2019 Apr 1;30(10):1352-1368. doi: 10.1089/ars.2017.7411. Epub 2018 Jan 5. Antioxid Redox Signal. 2019. PMID: 29183158 Free PMC article. Review.
-
Possible contributions of a novel form of synaptic plasticity in Aplysia to reward, memory, and their dysfunctions in mammalian brain.Learn Mem. 2013 Sep 18;20(10):580-91. doi: 10.1101/lm.031237.113. Learn Mem. 2013. PMID: 24049187 Free PMC article. Review.
-
Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease.Biochem Pharmacol. 2015 Oct 15;97(4):399-407. doi: 10.1016/j.bcp.2015.06.014. Epub 2015 Jun 18. Biochem Pharmacol. 2015. PMID: 26093062 Free PMC article. Review.
-
Time for a change in the research paradigm for Alzheimer's disease: the value of a chaotic matrix modeling approach.CNS Neurosci Ther. 2010 Aug;16(4):254-62. doi: 10.1111/j.1755-5949.2009.00117.x. Epub 2009 Apr 16. CNS Neurosci Ther. 2010. PMID: 20002628 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
